Paediatric study waivers for hyperuricemia treatment

Image: Envato

Shanton Pharma has reached agreement with the European Medicines Agency (EMA) on a paediatric investigation plan for Shanton’s lead investigational product, SAP-001.

The EMA has agreed to a product-specific full waiver in all paediatric age subsets with hyperuricemia of any cause other than chronic kidney disease or obesity. This waiver follows that of the Agreed initial Pediatric Study Plan filed with the US Food and Drug Administration (FDA) in May, which exempts SAP-001 from paediatric study requirements due to the extremely low prevalence of gout in children.

“We are pleased that the EMA and FDA have determined that paediatric clinical studies evaluating SAP-001 are not needed to support market authorisation applications for hyperuricemia and gout,” said Bing Li, chief executive officer.

“The EMA and FDA waivers significantly lessen the administrative and regulatory burden and lower the overall cost of clinical development of SAP-001.”

“The regulatory waivers granted by EMA and FDA allow Shanton to streamline its development of SAP-001. It is another step forward towards introduction of this potent First-in-Class oral urate-lowering therapy, that addresses unmet needs in gout not adequately controlled by approved oral urate-lowering medications,” said Robert Terkeltaub, professor emeritus of medicine at UCSD.

“SAP-001 has the potential to be a new entry point in the treatment paradigm for uncontrolled/refractory gout.”

SAP-001 is Shanton’s lead investigational compound for once-a-day oral urate-lowering therapy that targets uncontrolled/refractory gout. SAP-001’s urate lowering properties are based on a first-in-class mechanism-of-action and the programme has shown best-in-class efficacy and safety in gout patients with hyperuricemia refractory to standard of care xanthine oxidase inhibitor therapy in a recent phase 2b study.

Last year, Shanton received FDA’s Fast Track designation for SAP-001, based in part on its recent phase 2b results demonstrating the drug’s potential to meaningfully improve upon currently available urate lowering therapy for patients with uncontrolled/refractory gout, a serious condition for which there are considerable unmet medical needs.